Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury-Reference-Cited by-同舟云学术

Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury

Published:2017-02-16 Issue:2 Volume:163 Page:374-384
ISSN:1096-6080
Container-title:Toxicological Sciences
language:en
Short-container-title:

Author:

Otieno Monicah A¹,Snoeys Jan²,Lam Wing¹,Ghosh Avi¹,Player Mark R³,Pocai Alessandro³,Salter Rhys¹,Simic Damir¹,Skaggs Hollie¹,Singh Bhanu¹,Lim Heng-Keang¹

Affiliation:

1. Preclinical Development and Safety, Janssen Pharmaceuticals, Spring House, Pennsylvania 19477

2. Preclinical Development & Safety, Janssen Pharmaceutica NV, Beerse, Antwerpen BE 2340, Belgium

3. Cardiovascular & Metabolism, Janssen Pharmaceuticals, Spring House, Pennsylvania 19477

Publisher

Oxford University Press (OUP)

Subject

Toxicology

Link

http://academic.oup.com/toxsci/article-pdf/163/2/374/24935035/kfx040.pdf

Reference43 articles.

1. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump;Aleo;Hepatology,2014

2. Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling;Bloomer;Br. J. Clin. Pharmacol,2013

3. Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity;Boelsterli;Toxicol. Appl. Pharmacol,2003

4. Mechanisms of isoniazid-induced idiosyncratic liver injury: Emerging role of mitochondrial stress;Boelsterli;J. Gastroenterol. Hepatol,2014

5. Metabolism of xenobiotic carboxylic acids: Focus on coenzyme A conjugation, reactivity, and interference with lipid metabolism;Darnell;Chem. Res. Toxicol,2013

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future;Biomedicines;2024-06-21

2. Application of Covalent Binding Body Burden in the HμREL Human Hepatocyte Coculture Model for Reactivity Risk Assessment of Metabolically Low Turnover Drugs;Chemical Research in Toxicology;2024-03-26

3. The GPR40 novel agonist SZZ15‐11 improves non‐alcoholic fatty liver disease by activating the AMPK pathway and restores metabolic homeostasis in diet‐induced obese mice;Diabetes, Obesity and Metabolism;2024-03-18

4. Role of microsomal metabolism in bromfenac-induced cytotoxicity;Chemico-Biological Interactions;2024-03

5. G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?;Biomedicine & Pharmacotherapy;2024-03